Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells
Authors
Keywords
-
Journal
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
Volume 46, Issue 6, Pages 484-491
Publisher
Oxford University Press (OUP)
Online
2014-05-07
DOI
10.1093/abbs/gmu030
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF- B
- (2013) L. Bastian et al. CLINICAL CANCER RESEARCH
- U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
- (2013) T. M. Herndon et al. CLINICAL CANCER RESEARCH
- Immunomodulatory Effects of Histone Deacetylase Inhibitors
- (2013) P.V. Licciardi et al. CURRENT MOLECULAR MEDICINE
- Bortezomib and SAHA Synergistically Induce ROS-Driven Caspase-Dependent Apoptosis of Nasopharyngeal Carcinoma and Block Replication of Epstein-Barr Virus
- (2013) K. F. Hui et al. MOLECULAR CANCER THERAPEUTICS
- Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma
- (2013) María-Victoria Mateos et al. SEMINARS IN ONCOLOGY
- Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro
- (2012) Chongmei Huang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy
- (2012) Y. Zang et al. CLINICAL CANCER RESEARCH
- Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo
- (2012) G. Dasmahapatra et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells
- (2011) Ai-Hua Wang et al. ANNALS OF HEMATOLOGY
- Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo
- (2011) G. Dasmahapatra et al. MOLECULAR CANCER THERAPEUTICS
- The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
- (2010) G. Dasmahapatra et al. BLOOD
- PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells
- (2009) S. Bhalla et al. CLINICAL CANCER RESEARCH
- The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis
- (2009) Q-L Zhang et al. LEUKEMIA
- Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
- (2008) A. Moricke et al. BLOOD
- NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity
- (2008) F. Armstrong et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started